Impact of Obstructive Sleep Apnea On In-Hospital Outcomes in Patients With Atrial Fibrillation: A Retrospective Analysis of the National Inpatient Sample

Ahmed Brgdar 1, Jin Yi 1, Ahmad Awan 2, Mohamed Taha 2, Richard Ogunti 1, John Gharbin 1, Mehrotra Prafulla 2, Isaac Opoku 2

1. Internal Medicine, Howard University Hospital, Washington, DC, USA 2. Cardiovascular Disease, Howard University Hospital, Washington, DC, USA

Corresponding author: Ahmed Brgdar, ahmedbrgdar@gmail.com

Abstract

Background
Obstructive sleep apnea (OSA) is frequently seen with atrial fibrillation (AF) and is associated with increased cardiovascular morbidity, including hypertension, congestive heart failure, ischemic heart disease, and stroke. However, the impact of OSA on in-hospital outcomes of patients with AF is unclear.

Methodology
All patients aged ≥18 admitted primarily for AF between January 2016 and December 2017 were identified in the National Inpatient Sample database. They were then categorized into those with OSA and those without OSA. The primary outcome was in-hospital mortality. Unadjusted and adjusted analysis was performed on appropriate variables of interest.

Results
Of 156,521 primary AF hospitalizations, 15% of the patients had OSA. Baseline characteristics revealed no race disparity between the two groups. However, compared to those without OSA, the OSA group was younger and had a significantly higher proportion of males, obesity, heart failure, hypertension, chronic obstructive pulmonary disease, diabetes, and hyperlipidemia. Long-term anticoagulation and inpatient cardioversion were also higher in the OSA group. Following propensity matching, inpatient mortality was similar between the two groups [0.54% in OSA vs. 0.51% in non-OSA; adjusted odds ratio = 1.06 (95% confidence interval = 0.82-1.35)]. Similarly, OSA was not significantly associated with acute kidney injury, cardiac arrest, gastrointestinal bleed, acute stroke, or length of stay. However, the OSA group was less anemic and required fewer in-hospital blood transfusions.

Conclusions
Although OSA is highly prevalent in AF patients, inpatient mortality and cardiovascular outcomes such as cardiac arrest, stroke, or major bleeding were similar in AF patients with or without concomitant OSA with no significant differences in length of stay.

Introduction
Atrial fibrillation (AF) is the most common sustained arrhythmia globally, with a higher incidence and prevalence reported in developed countries compared to developing countries [1,2]. Currently, AF affects approximately six million patients in the United States alone and accounts for more than 454,000 hospitalizations each year [3,4]. Although a higher prevalence of AF has been reported with increasing age and among males, significant differences in AF prevalence by race and ethnicity have also been reported [5]. For example, in the Multi-Ethnic Study of Atherosclerosis (MESA) study, the age- and sex-adjusted incidence rates per 1,000 person-years of AF were 11.2 among non-Hispanic whites compared to 6.1 among Hispanics, 5.8 among non-Hispanic blacks, and 3.9 among Asians [6].

Patients with AF are disproportionately affected by obstructive sleep apnea (OSA) than patients without AF, with the prevalence of OSA in AF patients estimated between 21% and 74% [1]. In addition, OSA is an independent risk factor for several cardiovascular conditions such as coronary artery disease (CAD), myocardial infarction, systemic hypertension, pulmonary hypertension, and stroke [7-11]. Furthermore, OSA is associated with a significantly elevated risk of sudden cardiac death (SCD) [12,13] and is an independent
risk factor of stroke in patients with AF [14].

In addition, OSA has been associated with incident AF. In a large cohort of 5,542 obese sleep clinic patients under the age of 65, those with OSA had a two-fold higher risk of incident AF within five years of an OSA diagnosis than those without OSA [15]. Similarly, in another sleep clinic-based study with 6,841 predominantly middle-aged obese patients, OSA diagnosis and severity were independently associated with incident AF over 12 years of follow-up [16]. Among participants of the MESA cohort who were free of cardiovascular disease at baseline, those with a physician-diagnosed OSA had a 1.74-fold higher risk of incident AF during an average 8.5-year follow-up period [17]. These associations between AF and OSA are expected because they share many common risks factors such as increased age, sedentary lifestyle, extreme physical activity, smoking, excessive alcohol intake, obesity, hypertension, diabetes, coronary heart disease, myocardial infarction, and heart failure, all of which may induce structural and electrical remodeling of the atrium [2,5,18].

Notably, the presence of OSA in AF patients is known to decrease the effectiveness of both pharmacological and catheter-based pulmonary vein isolation (PVI) anti-arrhythmic treatment strategies [1]. Consistent with these observations, a retrospective analysis of Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) showed that OSA patients treated with continuous positive airway pressure (CPAP) treatment, the first-line therapy for OSA, were less likely to develop the permanent AF subtype compared to untreated patients [19]. Furthermore, among patients with AF and OSA, the risk of AF recurrence after electrical cardioversion or PVI was lower among CPAP users than non-users [20,21].

Although the relationship between AF and OSA has been relatively well-studied, there is a paucity of data reporting the impact of OSA on clinical outcomes in AF patients. In the one study we could identify, Holmqvist et al. reported that AF patients with OSA in the ORBIT-AF registry had a higher risk of hospitalization than those without OSA but had a similar risk of myocardial infarction, stroke, and cardiovascular-related mortality [19]. Moreover, little is known about in-hospital outcomes for patients with OSA and AF. Given these gaps in our understanding, we aimed to determine the impact of OSA on in-hospital outcomes in AF patients using data from the US National Inpatient Sample (NIS) database.

Materials And Methods

Data source

The NIS is a public inpatient healthcare database developed and maintained by the Healthcare Cost and Utilization Project (HCUP) under the sponsorship of the Agency for Healthcare Research and Quality to make national estimates of healthcare utilization, cost, quality, and outcomes [22]. NIS data are available from 1988 to 2019 with 48 participating states and the District of Columbia. Over seven million individual hospitalizations are recorded annually in the NIS database and include the principal diagnosis (primary discharge diagnosis), up to 29 secondary diagnoses, length of stay, up to 15 medical procedures performed during hospitalization, and total hospital costs.

The NIS databases adopted a self-weighing design in 2012 to represent a 20% stratified sample of all discharges from all HCUP-participating hospitals, covering nearly 97% of the US population in contrast to representing discharges from sampled hospitals before 2012 [22]. However, NIS excludes rehabilitation and long-term acute care hospitals [22]. Results from the NIS have been shown to correlate well with other hospitalization and discharge databases in the United States.

Study population

In this study, patients older than or equal to 18 years of age and hospitalized between January 2016 and December 2017 with AF as the primary diagnosis were identified from the NIS database using the International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code. The ICD-10 codes I48.20 corresponding to chronic AF and I48.91 corresponding to unspecified AF were used to identify the patient sample for this study. The study sample was categorized into two groups: AF patients with OSA (ICD-10 = G47.33) and AF patients without OSA. A propensity score-matched cohort was developed between AF with OSA and AF without OSA groups using a 1:1 nearest neighbor matching with a caliper of 0.01.

Patients’ baseline characteristics included age, sex, race/ethnicity, household income, insurance type, length of hospital stay, and comorbidities. Hospital characteristics included location (urban and rural). We then compared clinical outcomes among AF patients with OSA and those without OSA.

Outcomes

The primary outcome of this study was in-hospital mortality among AF patients with or without OSA. Secondary outcomes included acute kidney injury (AKI), acute stroke, cardiac arrest, gastrointestinal (GI) bleed, the need for blood transfusion, and length of hospital stay. Demographic and comorbid factors were identified as covariates.
Data were analyzed using Software for Statistics and Data Science (STATA V.14.2, Stata Corp., College Station, TX, USA). Descriptive statistics were used to describe the characteristics of AF patients with or without OSA. Categorical variables were presented as percentages and continuous variables as median ± interquartile range. We employed the propensity score method with standardized morbidity ratio (SMR) weighting to account for potential confounders.

SMR weight was calculated for each patient. Patients who had OSA were assigned a weight of 1, while those without OSA were weighed using PS/(1-PS). SMR weights standardized the distribution of measured demographic, hospital, and hospital characteristics in OSA patients to those without OSA [23]. The balance was assessed once the weights were applied by examining the standardized mean differences (SMD) of the two groups. SMD (calculated as the differences in means or proportions divided by a pooled estimated of the SD) is not as sensitive to sample size compared with traditional significance testing, and it helps identify clinically meaningful differences. A threshold of >10% in the absolute SMD was used as a significant imbalance between the two groups.

Outcome measures were compared between the two groups using the P-values of the chi-square unpaired t-tests. All statistical tests were two-sided, and tests with P-values of <0.05 were considered significant. Propensity score matching was performed using the MatchIt package for R software (R for Windows 3.2.4; The R Foundation for Statistical Computing, Vienna, Austria). Howard University Hospital Institutional Review Board exempted this study from a full review because it was determined to be a non-human study. We have utilized anonymized data available from a public data repository.

### Results

We identified a total of 156,521 patient records for AF hospitalizations, of which 23,678 (15%) had concurrent OSA. Baseline characteristics revealed no race disparity between the two groups, as shown in Table 1. However, patients with OSA were younger (65 ± 10 vs. 71 ± 13, p ≤ 0.01; SMD = 53%) compared to those without OSA. The OSA group also had a significantly higher proportion of males (64% vs. 49%, p < 0.01; SMD = 32%), obesity (50% vs. 14%, p ≤ 0.01; SMD = 71%), heart failure (42.9% vs. 36.6%; SMD = 12.77%), hypertension (83% vs. 77%; SMD = 6.24%), chronic obstructive pulmonary disease (33% vs. 24%; SMD = 20.32%), diabetes (41% vs. 27%; SMD = 29.19%), and hyperlipidemia (33% vs. 24%; SMD = 20.87%) were also higher in the OSA group (Table 1).
| Condition                        | OSA (Before) | Non-OSA (Before) | OSA (After) Matched | Non-OSA (After) Matched | SMD (%) |
|---------------------------------|--------------|------------------|---------------------|-------------------------|---------|
| Overweight                      | 1.48%        | 1.54%            | 1.48%               | 1.45%                   | 0.24%   |
| Coronary artery disease         | 35.28%       | 32.54%           | 35.28%              | 35.16%                  | 0.25%   |
| Heart failure                   | 42.92%       | 36.60%           | 42.92%              | 41.56%                  | 2.70%   |
| COPD                            | 33.05%       | 23.49%           | 33.05%              | 31.79%                  | 2.68%   |
| End-stage renal disease         | 2.61%        | 2.57%            | 2.61%               | 2.64%                   | 0.19%   |
| Chronic kidney disease          | 17.77%       | 15.44%           | 17.77%              | 17.27%                  | 1.30%   |
| Diabetes mellitus               | 40.86%       | 26.51%           | 40.86%              | 40.25%                  | 1.25%   |
| Hyperlipidemia                  | 57.78%       | 49.08%           | 57.78%              | 58.55%                  | 1.57%   |
| Smoking                         | 42.13%       | 38.95%           | 42.13%              | 41.98%                  | 0.30%   |
| Pulmonary hypertension          | 1.40%        | 0.95%            | 1.40%               | 1.28%                   | 1.01%   |
| Malignancy                      | 3.54%        | 5.50%            | 3.54%               | 3.34%                   | 1.10%   |
| Alcohol abuse                   | 4.42%        | 5.22%            | 4.42%               | 4.18%                   | 1.17%   |
| Drug abuse                      | 2.10%        | 2.36%            | 2.10%               | 1.92%                   | 1.24%   |
| Hemorrhagic stroke              | 9.68%        | 11.06%           | 9.68%               | 9.38%                   | 1.04%   |
| Cardiogenic shock               | 0.54%        | 0.51%            | 0.54%               | 0.52%                   | 0.29%   |
| Other shocks                    | 0.19%        | 0.14%            | 0.19%               | 0.16%                   | 0.59%   |
| Hypotension                     | 5.99%        | 6.71%            | 5.99%               | 5.55%                   | 1.89%   |
| STEMI                           | 1.82%        | 2.43%            | 1.82%               | 1.73%                   | 0.73%   |
| Long-term anticoagulant         | 35.26%       | 28.55%           | 35.26%              | 34.68%                  | 1.21%   |
| Cardioversion                   | 26.93%       | 17.67%           | 26.93%              | 26.46%                  | 1.07%   |

**TABLE 1: Baseline patient characteristics before and after matching.**

COPD: chronic obstructive pulmonary disease; OSA: obstructive sleep apnea; SMD (%): standardized mean difference (in percentage); STEMI: ST-segment elevation myocardial infarction

Following propensity matching, inpatient mortality, our primary outcome of interest, was similar between the two groups [0.54% in OSA vs. 0.51% in non-OSA, adjusted odds ratio = 1.06 (95% confidence interval (CI) 0.82-1.35)] (Table 2). There was no statistically significant difference between the two groups with regards to AKI (p = 0.38), cardiac arrest (p = 0.24), GI bleed (p = 0.563), acute stroke (p = 0.072), or length of stay (p = 0.67). However, the OSA group was less anemic and required fewer in-hospital blood transfusions (0.8% vs 1.0%, p = 0.04; 95% CI = 0.68-0.98).
|                              | OSA   | Non-OSA | aOR (95% CI)       | P-value |
|------------------------------|-------|---------|--------------------|---------|
| Inpatient mortality (%)      | 0.54  | 0.51    | 1.06 (0.82-1.35)   | 0.65    |
| Acute kidney injury (%)      | 12.3  | 12.5    | 0.98 (0.92-1.03)   | 0.38    |
| Acute stroke (%)             | 0.35  | 0.40    | 0.75 (0.59-1.02)   | 0.072   |
| Mean length of stay* (days)  | 3.4   | 3.43    |                    | 0.67    |
| Cardiac arrest (%)           | 0.38  | 0.31    | 1.20 (0.88-1.63)   | 0.24    |
| GI bleed (%)                 | 1     | 1.10    | 0.563 (0.79-1.13)  | 0.24    |
| Need for blood transfusion (%)| 0.80  | 1       | 0.83 (0.68-0.98)   | 0.04    |

TABLE 2: Association of OSA and outcomes in patients with AF.

*Length of stay among those who survived till hospital discharge.

aOR: adjusted odds ratio; AF: atrial fibrillation; CI: confidence interval; OSA: obstructive sleep apnea

Discussion

Whether OSA is associated with higher inpatient mortality has been controversial. Some studies have shown that OSA is associated with a reduction in both intensive care unit and hospital mortality [24,25]. Furthermore, a recent nationwide analysis using the 2004-2014 NIS data showed that patients with concomitant diagnoses of AF and OSA have lower inpatient all-cause mortality than those with only AF [26]. In contrast, an analysis of the ORBIT-AF registry demonstrated worse symptoms and higher risks of hospitalization but similar mortality, major adverse cardiovascular outcomes, and AF progression rates in OSA patients with AF [26]. Our study aligned more with the notion that mortality was similar between the OSA and non-OSA groups; inpatient mortality was approximately 0.5% in both groups. Moreover, AKI, cardiac arrest, GI bleed, and acute stroke, which were the secondary outcomes of this study, were similar in AF patients with or without OSA. Although earlier studies have suggested that OSA patients have a longer length of stay after cardiac surgery [27] and are more likely to be readmitted within 30 days of discharge [27,28], we found no difference in the length of hospital stay between AF patients with OSA or without OSA.

Obesity, type 2 diabetes mellitus, hypercholesterolemia, and hypertension are well-studied risk factors of both AF and sleep apnea [29]. As expected, in our study population, nearly 50% of patients in the OSA group were obese compared to 14% in the non-OSA group. We noted that a middle-aged, overweight man is a typical OSA patient; this aligns with earlier research that OSA is seen more frequently in men than women [20]. Severity in both genders increases with increasing body mass index and age, a greater report of the symptoms, and decreased nadir saturation during sleep study [30,31]. Our study reaffirmed that both hyperlipidemia (58% vs. 49%; SMD = 17.60%) and hypertension (83% vs. 77%; SMD = 16.24%) were more common in patients with OSA admitted for AF. This was consistent with studies supporting OSA as the most prevalent secondary contributor to elevated blood pressure in patients with resistant hypertension [32]. Increased sympathetic activity, intrathoracic pressure during episodes of apnea resulting in hypertension, and excessive rates of venous return have been postulated as possible mechanisms for the development of AF in OSA [33].

Marked racial differences exist in the association of OSA with cardiovascular disease (CVD), and some studies have demonstrated a disproportional burden of CVD among blacks with a marked racial disparity in care and outcomes in the United States [34-36]. However, the baseline characteristics of our study population did not show race disparity between the OSA group admitted for AF and the non-OSA group, which was consistent with most of the available data on the prevalence and risk factors of OSA conducted among whites of European descent, US Hispanics, and African Americans [37]. Despite the lack of data in Asia, the prevalence is approximately 2.1-7.5%, comparable to the Caucasian population [38].

Long-term anticoagulation was higher in the OSA group than in the non-OSA group, consistent with patients in the ORBIT-AF registry [19]. The prophylactic use of anticoagulants is in line with findings that AF patients with OSA have higher CHA2DS2 and CHA2DS2-VASc scores, which predicts a higher risk of stroke [39]. Moreover, OSA is a contributing cause to the progression of paroxysmal AF to persistent AF [40], and in patients receiving anticoagulation therapy, those with persistent AF have a higher risk of stroke with worse survival compared to those with paroxysmal AF [41]. Moreover, the OSA group had higher inpatient cardioversion than AF patients without OSA. It has been hypothesized that CPAP treatment for OSA may help maintain sinus rhythm after electrical cardioversion [1], although a recent randomized trial showed no differences in AF recurrences after direct current cardioversion between those treated with CPAP versus
usual care [42]. Additional studies are needed to evaluate CPAP adherence and its utility in preventing recurrence of AF.

Earlier studies have also suggested that OSA might be a risk factor for SCD. A retrospective study found that the relative risk of SCD was 2.57-fold higher between midnight and 6 a.m. in patients with OSA compared with the general population [12]. A 2013 longitudinal study showed that nocturnal hypoxemia, a critical pathophysiological feature of OSA, strongly predicted SCD independent of well-established risk factors [13]. These electrophysiologic changes associated with OSA may contribute to nocturnal SCD in patients with channeleopathies and altered repolarization [43,44]. In contrast to these findings, AF patients with OSA in our study did not have increased cardiac arrest odds than the non-OSA group (p = 0.24). Future studies with an adequately large cohort with information about OSA at baseline and a sufficient longitudinal follow-up period are warranted to clarify the association between OSA and SCD.

There are some limitations of our study that may affect the generalizability of the findings. First, our analysis was limited to in-hospital outcomes and does not reflect post-discharge care and events. Second, our analysis was not stratified by severity due to the limitation of the NIS database; hence, stratifying for AF and OSA severity in estimating the outcomes of interest is not possible. In addition, details of treatment for OSA, diagnostic modalities, and comorbidities were not available in the database. Finally, given the nature of this retrospective analysis, selection bias can be expected; however, propensity score matching was performed to avoid possible bias.

**Conclusions**

Although OSA is highly prevalent in AF, inpatient mortality and cardiovascular outcomes such as cardiac arrest, stroke, or major bleeding were similar in AF patients with or without concomitant OSA with no significant differences in length of stay. However, prospective trials are needed to evaluate in-hospital outcomes of AF patients based on sleep apnea severity. In addition, universal measures to determine sleep apnea severity and guide OSA therapy for patients with AF need further investigation.

**Additional Information**

**Disclosures**

**Human subjects:** All authors have confirmed that this study did not involve human participants or tissue.

**Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue.

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**Acknowledgements**

The authors acknowledge the contributions of Dr. Urooj Fatima and Dr. Daniel Larbi of Howard University Hospital, Washington, DC, USA, for their critical review of this manuscript.

**References**

1. Linz D, McEvoy RD, Cowie MR, et al.: Associations of obstructive sleep apnea with atrial fibrillation and continuous positive airway pressure treatment: a review. JAMA Cardiol. 2018; 3:552-40. 10.1001/jamacardio.2018.0095
2. Huang B, Liu H, Scherlag BJ, et al.: Atrial fibrillation in obstructive sleep apnea: neural mechanisms and emerging therapies. Trends Cardiovasc Med. 2021, 31:127-52. 10.1016/j.tcm.2020.01.006
3. Benjamin EJ, Muntner P, Alonso A, et al.: Coronary artery disease and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk: the Multi-Ethnic Study of Atherosclerosis. Ann Epidemiol. 2015, 25:1142-7. 10.1016/j.amepi.2015.05.063
4. Staerk L, Sherar JA, Ko D, Benjamin EJ, Helm RH: Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017, 120:1501-17. 10.1161/CIRCRESAHA.117.309732
5. Rodriguez CJ, Soliman EZ, Alonso A, Swett K, Okin PM, Goff DC Jr, Heekbert SR: Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: the Multi-Ethnic Study of Atherosclerosis. Ann Epidemiol. 2015, 25:71-6, 76.e1. 10.1016/j.amepi.2014.11.024
6. Schäfer H, Koecher U, Ewig S, Harper E, Tasic S, Lüderitz B: Obstructive sleep apnea as a risk marker in coronary artery disease. Cardiology. 1999, 92:79-84. 10.1159/000006952
7. Schafman E, Ewig S, Harper E, Tasic S, Lüderitz B: Obstructive sleep apnea as a risk marker in coronary artery disease. Cardiology. 1999, 92:79-84. 10.1159/000006952
heart disease and stroke in men. Br Med J (Clin Res Ed). 1987, 294:645. 10.1136/bmj.294.6572.645-c
10. Nieto FJ, Young TB, Lind BK, et al.: Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000, 283:1829-36. 10.1001/jama.283.14.1829
11. Prisco DL, Sica AL, Talwar A, et al.: Correlation of pulmonary hypertension severity with metrics of comorbid sleep-disordered breathing. Sleep Breath. 2011, 15:635-9. 10.1007/s11325-010-0411-y
12. Gami AS, Howard DE, Olson EI, Somers VK: Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med. 2005, 352:1206-14. 10.1056/NEJMoa041852
13. Gami AS, Olson EI, Shen WR, et al.: Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. J Am Coll Cardiol. 2015, 62:610-6. 10.1016/j.jacc.2015.04.080
14. Varazan DM, Smyrnis U, Usatii N, Butler A, Petreti IR, Mender J, Waznoffsky MK: Effect of obstructive sleep apnea on frequency of stroke in patients with atrial fibrillation. Am J Cardiol. 2015, 115:461-5. 10.1016/j.amjcard.2014.11.027
15. Gami AS, Hodge DO, Herges RM, Olson EI, Nykodym J, Kara T, Somers VK: Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol. 2007, 49:565-71. 10.1016/j.jacc.2006.08.060
16. Cadby G, Mckrdle N, Briffa T, Hillman DR, Simpson L, Knuiman M, Hung J: Severity of OSA is an independent predictor of incident atrial fibrillation hospitalization in a large sleep clinic-coping cohort. Chest. 2015, 148:945-52. 10.1378/chest.15-0229
17. Lin GM, Colangelo LA, Lloyd-Jones DM, et al.: Association of sleep apnea and snoring with incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2015, 182:49-57. 10.1095/aje/kov004
18. Kwon Y, Koene RJ, Johnson AR, Lin GM, Ferguson JD: Sleep, sleep apnea and atrial fibrillation: questions and answers. Sleep Med Rev. 2018, 39:154-42. 10.1016/j.smrv.2017.08.005
19. Holmquist F, Gau N, Zhu Z, et al.: Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation—results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2015, 169:647-54.e2. 10.1016/j.ahj.2014.12.024
20. Kanagala R, MuruI NS, Friedman PA, et al.: Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation. 2003, 107:2589-94. 10.1161/01.CIR.0000086537.25994.21
21. Fein AS, Shvilkin A, Shah D, et al.: Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol. 2015, 62:500-5. 10.1016/j.jacc.2015.03.052
22. Agency for Healthcare Research and Quality (2011). Overview of the National (Nationwide) Inpatient Sample (NIS). (2021). Accessed: November 18, 2021: http://www.hcup-us.ahrq.gov/nisoverview.jsp.
23. Stürmer T, Wyss R, Glynn RJ, Brookhart MA: Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. Intern Med. 2014, 275:570-80. 10.1111/joim.12197
24. Bolona E, Hahn PY, Afeessa B: Intensive care unit and hospital mortality in patients with obstructive sleep apnea. J Crit Care. 2015, 30:178-80. 10.1016/j.jcirl.2014.10.001
25. Lyons PG, Zadravecz FJ, Edelson DP, Mokhlesi B: Obstructive sleep apnea and adverse outcomes in surgical and nonsurgical patients on the wards. J Hosp Med. 2015, 10:592-8. 10.1002/jhm.2404
26. Dekhordi SH, Gholtabar N, Gholtabar F, et al.: Effects of obstructive sleep apnea on the outcomes of atrial fibrillation: a nationwide analysis. J Am Coll Cardiol. 2018, 71:525-10. 10.1016/j.jacc.2018.03.0166-0
27. Gali B, Glasgow AE, Greason KL, Johnson RL, Albright RC, Habermann EB: Postoperative outcomes of patients with obstructive sleep apnea undergoing cardiac surgery. Ann Thorac Surg. 2020, 110:1534-32. 10.1016/j.athoracsur.2019.12.082
28. Scalzitti NJ, O’Connor PD, Nielsen SW, et al.: Obstructive sleep apnea is an independent risk factor for hospital readmission. J Clin Sleep Med. 2018, 14:755-8. 10.5664/jcsm.7098
29. Jehan S, Zizi F, Pandi-Perumal SR, et al.: Obstructive sleep apnea and obesity: implications for public health. Sleep Med Disord. 2017, 1:00019. 10.15406/smrdij.2017.01.00019
30. Bixler EO, Vgontzas AN, Ten Have T, Tyson K, Kales A: Effects of age on sleep apnea in men: I. Prevalence and severity. Am J Respir Crit Care Med. 1998, 157:144-8. 10.1164/ajrccm.157.1.9706079
31. Peppard PE, Young T, Barna T, Mellen RB, Hagen EW, Hla KM: Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2015, 177:1006-14. 10.1093/aje/kws342
32. Pedrosa RP, Drager LF, Gonçaga CC, et al.: Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011, 58:811-7. 10.1161/HYPERTENSIONAHA.111.179788
33. Lazzar B, Faulx MD: Obstructive sleep apnea and cardiac arrhythmias: a contemporary review. J Clin Med. 2021, 10:5785. 10.3390/jcm10173785
34. Roger VL, Go AS, Lloyd-Jones DM, et al.: Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2012, 125:188-97. 10.1161/CIRCULATIONAHA.111.1382456446
35. Menahag GA, Mokdad AH, Ford ES, Greenland KJ, Croft JB: State of disparities in cardiovascular health in the United States. Circulation. 2005, 111:1235-41. 10.1161/CIRCULATIONAHA.104.151856.76824.04
36. Mitchell JE, Hellkamp AS, Mark DB, Anderson J, Poole JE, Lee KL, Bardi GH: Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2008, 155:561-6. 10.1016/j.ahj.2007.10.022
37. January CT, Wann LS, Calkins H, et al.: 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: an update of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019, 74:104-52. 10.1016/j.jacc.2019.01.011
38. Lam B, Lam DC, Ip MS: Obstructive sleep apnoea in Asia. Int J Tuberc Lung Dis. 2007, 11:2-11.
39. Szymanski FM, Filipiak KJ, Platek AE, Hryniewicz-Szymanska A, Karpinski G, Opolski G: Assessment of CHA2DS2 and CHA-VASc scores in obstructive sleep apnea patients with atrial fibrillation. Sleep Breath. 2015, 19:531-7. 10.1007/s11325-014-1042-5
40. Hohl M, Linz B, Böhm M, Linz D: Obstructive sleep apnea and atrial arrhythmogenesis. Curr Cardiol Rev. 2014, 10:362-8. 10.2174/1573403x1004140707125137
41. Steinberg BA, Helikamp AS, Lokhnygina Y, et al.: Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J. 2015, 36:288-96. 10.1093/eurheartj/ehu359
42. Caples SM, Mansukhani MP, Friedman PA, Somers VK: The impact of continuous positive airway pressure treatment on the recurrence of atrial fibrillation post cardioversion: a randomized controlled trial. Int J Cardiol. 2019, 278:153-6. 10.1016/j.ijcard.2018.11.100
43. Zheng J, Zheng D, Su T, Cheng J: Sudden unexplained nocturnal death syndrome: the hundred years' enigma. J Am Heart Assoc. 2018, 7:10.1161/JAHA.117.007837
44. Tobaldini E, Brugada J, Bernito B, et al.: Cardiac autonomic control in Brugada syndrome patients during sleep: the effects of sleep disordered breathing. Int J Cardiol. 2015, 168:5267-72. 10.1016/j.ijcard.2013.04.137